NASDAQ · Healthcare
Invest in Oculis stock from India
Indian and foreign residents can buy Oculis (OCS) shares directly through Paasa.
By Paasa · Updated
Oculis at a glance
- Price
- $9.27-$0.14 (1.49%)
- Market cap
- $529.96M
- Day range
- $9.10 – $9.40
- P/E
- -5.49
- Dividend yield
- None
- Volume
- 239.57K
- 1 month
- -28.53%
- 6 months
- -62.91%
- YTD
- -53.58%
- 1 year
- -47.42%
- 5 years
- -4.14%
Oculis statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 0.0 | CHF 686.0K | CHF 0.0 | CHF 0.0 | CHF 0.0 |
| Gross profit | CHF 0.0 | −CHF 51.4M | CHF 0.0 | CHF 0.0 | CHF 0.0 |
| Operating income | −CHF 79.1M | −CHF 73.2M | −CHF 80.7M | −CHF 32.4M | −CHF 13.2M |
| Net income | −CHF 94.5M | −CHF 85.8M | −CHF 88.8M | −CHF 38.7M | −CHF 18.6M |
| Earnings per share | −CHF 1.81 | −CHF 2.12 | −CHF 2.97 | −CHF 1.18 | −CHF 0.57 |
| EBITDA | −CHF 93.4M | −CHF 85.5M | −CHF 87.1M | −CHF 31.9M | −CHF 13.2M |
| Total assets | CHF 236.2M | CHF 120.4M | CHF 114.4M | CHF 37.1M | CHF 58.0M |
| Total debt | CHF 2.3M | CHF 1.2M | CHF 605.0K | CHF 123.1M | CHF 114.3M |
| Cash and short-term investments | CHF 213.3M | CHF 98.7M | CHF 91.7M | CHF 19.8M | CHF 46.3M |
| Shareholders' equity | CHF 196.3M | CHF 73.4M | CHF 93.7M | −CHF 98.0M | −CHF 61.0M |
| Operating cash flow | −CHF 62.2M | −CHF 47.5M | −CHF 53.8M | −CHF 25.1M | −CHF 13.8M |
| Free cash flow | −CHF 62.5M | −CHF 47.7M | −CHF 53.9M | −CHF 28.6M | −CHF 13.9M |
| Capital expenditure | −CHF 287.5K | −CHF 230.0K | −CHF 48.0K | −CHF 3.5M | −CHF 28.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Nurix Therapeutics | NRIX | $23.01 | $2.39B |
| Kodiak Sciences | KOD | $32.35 | $2.02B |
| UroGen Pharma | URGN | $41.35 | $2.01B |
| Xencor | XNCR | $23.80 | $1.76B |
| Nektar Therapeutics | NKTR | $57.06 | $1.64B |
| Mind Medicine (MindMed) | MNMD | $20.69 | $1.56B |
| AnaptysBio | ANAB | $51.00 | $1.51B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $26.00
- High
- $45.00
- Median
- $38.00
- Consensus
- $36.75
Ratings: 9 buy · 0 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Oculis from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search OCS and buy
Find Oculis by name or by its ticker, OCS, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Oculis from India
What Oculis does
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Oculis operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Oculis shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Oculis share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Oculis stock from India?
Yes. Indian residents and NRIs can buy Oculis (OCS) shares directly through Paasa. Oculis is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Oculis share?
No. You can buy part of one Oculis share and add to your position over time. One share is $9.27, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Oculis dividends taxed for Indian investors?
Oculis trades on NASDAQ but is domiciled in Switzerland, so any withholding on its dividends follows that country's rules rather than those of the US. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Oculis shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.